VEGFA and neoplasm: The initial beneficial effects of bevacizumab are only transient given that GBM tumors—in a similar manner to radiation therapy—inevitably recur during treatment by employing alternative pathways that sustain tumor growth when VEGF signaling is inhibited [173].